glp 1 agonists muscle loss Hidden Risks of GLP-1 Inhibitors: and "Ozempic Face" Frontiers | Exploring the multifaceted

Safety is a critical factor to consider when evaluating long-term cardiometabolic therapies

however, trials developed mainly to evaluate the long-term impact of tirzepatide on cardiovascular events, including stroke, are currently in progress [42]

Torley D, Bellus GA, Munro CS

How could a hormone produced in our gut that regulates appetite, satiety and glucose levels be so deeply intertwined to our biology have such multi-factorial effects

Neuroprotective Effects of GLP-1 Receptor Agonists in Neurodegenerative Disorders: A Large-Scale Propensity-Matched Cohort Study

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial